Objective: To assess the effects of consuming foods containing oat b-glucan on blood pressure, carbohydrate homeostasis and biomarkers of oxidative stress. Design: A randomized, double-blind, controlled clinical trial. Setting: The trial was conducted at two clinics. Subjects and interventions: Ninety-seven men and women with resting systolic blood pressure 130-179 mm Hg and/or diastolic blood pressure 85-109 mm Hg were randomly assigned to consume foods containing oat b-glucan or control foods for 12 weeks. Resting blood pressures, insulin and glucose values before and after standard breakfast meals, and four biomarkers of oxidative stress were measured before and at the end of the treatment period. Results: Changes from baseline to week 12 in mean peak insulin and incremental area under the insulin curve differed significantly between groups (P ¼ 0.037 and 0.034, respectively), with the b-glucan group showing declines and the control group remaining essentially unchanged. Blood pressure responses were not significantly different between groups overall. However, in subjects with body mass index above the median (31.5 kg/m 2 ), both systolic (8.3 mm Hg, P ¼ 0.008) and diastolic (3.9 mm Hg, P ¼ 0.018) blood pressures were lowered in the b-glucan group compared to controls. No significant differences in biomarkers of oxidative stress were observed between treatments. Conclusions: The results of the present trial suggest beneficial effects of foods containing b-glucan from oats on carbohydrate metabolism, and on blood pressure in obese subjects.
Introduction
Hypertension is a major risk factor for coronary heart disease and stroke (National High Blood Pressure Education Program, 2003) . Elevated blood pressure is also a component of the metabolic syndrome, a cluster of risk factors for atherosclerotic disease and diabetes mellitus that occur together more often than would be predicted by chance (Haffner and Taegtmeyer, 2003; Scott, 2003) . Approximately 50% of people with hypertension have impaired insulinmediated glucose uptake and hyperinsulinemia (Reaven et al., 1996) . Insulin resistance and compensatory hyperinsulinemia are thought to be central pathophysiologic features of the metabolic syndrome (Fonseca, 2003; Haffner and Taegtmeyer, 2003; Scott, 2003) , and a growing body of evidence suggests that disturbances of carbohydrate metabolism may play a role in the development of hypertension in some individuals (Reaven et al., 1996) . Several mechanisms have been proposed to explain the associations between insulin resistance, hyperinsulinemia and hypertension, including the actions of insulin to enhance renal sodium reabsorption and stimulate the sympathetic nervous system, as well as the anabolic effects of insulin on cardiac and vascular tissues (Landsberg, 1999; Fonseca, 2003; Scott, 2003) .
The insulin sensitizing drugs thiazolidinediones and metformin have been shown to reduce blood pressure in hypertensive subjects (Fonseca, 2003) . Another drug that affects carbohydrate metabolism, acarbose, has also been shown to favorably alter blood pressure (Chiasson et al., 2003) . This complex oligosaccharide acts by inhibiting a-glucosidase activity, which slows starch digestion and delays glucose absorption, thereby reducing the increases in postprandial glucose and insulin levels. The Study TO Prevent Non-Insulin Dependent Diabetes Mellitus (STOP-NIDDM) assessed the effects of acarbose on the development of hypertension in a group of 1429 subjects with impaired glucose tolerance (Chiasson et al., 2003) . During 3.3 years of follow-up, blood pressure was modestly lower and new-onset hypertension was reduced by 34% in the acarbose group, compared to placebo (Chiasson et al., 2003) .
Dietary fibers that form viscous gels in the gastrointestinal tract also slow the absorption of glucose (Wolever et al., 1991a, b) . Because viscous soluble fibers and acarbose affect postprandial glucose and insulin levels in a similar manner, it is reasonable to hypothesize that consuming such fibers may also reduce blood pressure and lower the risk for hypertension. Indeed, a number of studies have shown an association between increased consumption of viscous soluble fibers and lower blood pressure (Landin et al., 1992; He et al., 1995; Burke et al., 2001; Saltzman et al., 2001; Keenan et al., 2002; Pins et al., 2002; Bazzano et al., 2003) , although this finding has not been universal (Davy et al., 2002) .
Increased oxidative stress is a feature of cardiovascular disease risk factors such as hypertension (Griendling et al., 2000) , diabetes (Jain et al., 1989; Keaney et al., 2003) and obesity (Keaney et al., 2003) . Compounds with antioxidant activities have been identified in oats (Collins, 1986, Peterson and Qureshi, 1993; Chen et al., 2004) .
The aim of the current study was to assess the effects of consuming foods containing oat b-glucan, a viscous soluble fiber, on blood pressure, postprandial glucose and insulin levels, and four biomarkers of oxidative stress in overweight and obese subjects with elevated blood pressure.
Participants and methods

Subjects
Participants included men and women X40 years of age with elevated systolic blood pressure (between 130 and 179 mm Hg) and/or diastolic blood pressure (between 85 and 109 mm Hg) that was untreated or suboptimally controlled with one or two antihypertensive medications. Subjects were also required to have a waist circumference measurement of X87 cm for women and X95 cm for men and had to be willing to maintain their current weight and activity level throughout the study period. Subjects were asked to abstain from dietary fiber supplements and cereal products (other than the study products) during the trial and had to be willing to consume 120 ml of skim milk with study meals administered at the clinic. This study was performed according to Good Clinical Practice Guidelines, the Declaration of Helsinki (U.S. Department of Health and Human Services, 1996) and US 21 CFR Part 50 -Protection of Human Subjects, and Part 56 -Institutional Review Boards. All subjects were normally active and otherwise judged to be in good health on the basis of medical history and physical examination, and signed an informed consent document that was approved by an institutional review board (Quorum IRB, Seattle, WA, USA).
Subjects were excluded if they had systolic blood pressure X180 mm Hg and/or diastolic blood pressure X110 mm Hg, or if there was evidence of any secondary cause of hypertension. Use of over-the-counter drugs containing pseudoephedrine or other vasoconstrictors was prohibited. Subjects were also excluded if they had a mid-upper arm circumference X42 cm at screening or daily fiber intake X20 g/day based on a 48-h dietary recall administered at visit 1 (week À4). Women who were pregnant, planning to be pregnant during the study period, lactating, or women of childbearing potential who were not using an approved method of contraception were excluded.
Use of omega-3 fatty acid or herbal supplements was prohibited during the study period. Vitamin/mineral supplement intake was allowed if stable throughout the trial. Use of weight-loss drugs was prohibited, as was use of systemic corticosteroids, androgens, phenytoin or erythromycin. Use of thyroid replacement or lipid-altering drugs was allowed, provided the dose had been stable for X2 months before enrollment.
Subjects who received drugs other than stable-dose aspirin for regulating hemostasis were excluded, as were subjects with severe asthma or other conditions that required periodic use of oral steroids. Those with a recent history (within 6 months before visit 1) or current diagnosis of unstable angina, congestive heart failure, myocardial infarction, revascularization, hypothyroidism, significant anemia, hyperadrenocorticalism or significant gastrointestinal, renal, pulmonary, hepatic or biliary disease were excluded. Also excluded were subjects with diabetes mellitus, those with a history of cancer (except non-melanoma skin cancer) within the previous 5 years, those with a recent history of (within past 12 months) or strong potential for alcohol or substance abuse, and those who had participated in a clinical trial within 30 days of the screening visit. Individuals who had a condition the investigator believed would interfere with his/her ability to provide informed consent, comply with study instructions or which might confound the interpretation of the study results or put the subject at undue risk were also excluded.
Experimental design
The current study used a randomized, double-blind, controlled design with two parallel treatment arms. The trial was conducted at two sites and included eight clinic visits (three screening visits (weeks À4, À2 and À1), one at baseline (week 0) and four during treatment (weeks 4, 8, 11 and 12) ). At visit 2, subjects were instructed to follow the United States National Cholesterol Education Program (NCEP) Therapeutic Lifestyle Changes (TLC) diet (National Cholesterol Education Program, 2002) , which was maintained throughout the trial. All clinic visits were conducted in the morning to decrease variability in blood pressure measurements. Subjects were required to abstain from all foods and beverages except water for at least 10 h before clinic visits, and to abstain from consuming alcohol 24 h before clinic visits. Subjects were also asked to refrain from smoking and taking blood pressure medications the morning of clinic visits.
At the initial screening visit (week À4), subjects were advised to maintain their body weight and usual level of physical activity throughout the trial. At each clinic visit, subjects were specifically asked about any unusual or vigorous activity that they had participated in over the past 48 h.
At baseline (week 0), eligible subjects were randomly assigned to receive one of two sets of food products for the 12-week treatment period (supplied by The Quaker Oats Company, Barrington, IL, USA). The oat b-glucan group received (1) a ready-to-eat (RTE) cold cereal made with oat bran, (2) oatmeal and (3) a powdered form of oat b-glucan. The control groups received (1) a low-fiber RTE cold wheatbased cereal (2) a low-fiber hot cereal and (3) a control maltodextrin powder. Nutritional compositions of the study products are shown in Table 1 .
Study products
Subjects were instructed to consume three servings of study products per day (one hot cereal, one cold cereal and one packet of powder). One cereal serving was to be eaten for breakfast, and the other as a snack or part of a meal in place of other similar carbohydrate/grain-based foods. All or half of the daily portion of the powder mix (oat b-glucan or maltodextrin control) was to be cooked with the hot cereal, and the remaining daily portion, if applicable, was to be combined with a food or beverage that was normally consumed. Sugar or artificial sweetener could be used with the study products as desired.
Measurements/assessments
Subjects received 3-day diet records at screening (week À4 and week À1), baseline (week 0) and near the end of treatment (week 11). These diet records were completed during the week before the next clinic visit. Study product consumption was evaluated by subject interview and by counting unused study product packages returned to the clinic. The Stanford 7-day physical activity recall questionnaire (Sallis et al., 1985) was administered at baseline (week 0) and at the end of the treatment period (week 12).
Clinical laboratory measurements were conducted by Medical Research Laboratories (MRL, Bristol, TN, USA). All laboratory samples were frozen at the site and batch shipped to MRL. Plasma glucose and insulin levels were measured Blood pressure was measured at each visit using the Welch Allyn Vital Signs Monitor, Model 52000-E1 (Welch Allyn Inc., Skaneateles Falls, NY, USA) automated blood pressure device while the subject was seated in a quiet room with the lights dimmed. Subjects were instructed to rest quietly throughout the procedure, but to remain awake. Blood pressure was measured six times at 3-min intervals. The first two measurements (0 and 3 min) were ignored, and the last four measurements (6, 9, 12 and 15 min) were averaged to determine systolic and diastolic blood pressures. For subjects taking blood pressure medication, the time of the most recent dose was reported to the study coordinator at each clinic visit and was standardized from visit to visit.
At weeks À2, 0 and 12, subjects consumed a standardized breakfast consisting of 120 ml skim milk with 90 g cold cereal (control product at week À2 for all subjects, and then the randomly assigned oat b-glucan or control test products at weeks 0 and 12). Subjects were allowed 15 min to consume the breakfast. Assessments of blood glucose and insulin levels were made pre-meal and at t ¼ 30, 60, 90 and 120 min, with t ¼ 0 indicating the start of breakfast consumption. Peak and incremental area under the curve (AUC) values were calculated for postprandial insulin and glucose responses. AUC calculations were completed according to the method of Wolever et al. (1991a, b) .
Measurements of waist and arm circumferences were made according to procedures described by Heyward (1984) . Two measurements were taken at each site. If these differed by 40.5 cm, a third measurement was taken, then the two closest values were averaged.
At the second clinic visit (week À2), subjects received diet instruction regarding the NCEP TLC diet. They were also informed how to appropriately replace foods in their diet with the study products (primarily breakfast and snack foods) in order to maintain usual energy intake. Three-day diet records were turned in at weeks À2, 0, 4 and 12. All foods, beverages and supplements consumed each day for 3 days (two weekdays, one weekend day), including the study product, were recorded. These were analyzed using the University of Minnesota Nutrition Data System for Research, Minneapolis, MN, USA, version 4.03_31 software (2000) .
Statistical methods
Statistical analyses were completed using SAS version 8.2 for the personal computer (SAS Institute, Cary, NC, USA). Baseline comparabilities of treatment groups for demographic, anthropometric, blood pressure, insulin, glucose and biomarkers of oxidative stress were assessed by analysis of variance (ANOVA) or w 2 tests as appropriate. ANOVA models were generated to compare responses (absolute or percent change from baseline to end of treatment) between groups for outcome variables including blood pressures, insulin and glucose values, body weight, waist circumference, dietary intakes, physical activity score and biomarkers of oxidative stress. Results are presented for a per-protocol sample that excluded data from subjects for protocol violations, including changes in drug regimen during the study period, or inadequate compliance (o80% of scheduled servings of study product consumed). All decisions regarding inclusion in the per-protocol sample were made by personnel who were blinded to treatment group before locking of the study database. Baseline blood pressures were calculated as the average of values obtained at weeks À1 and 0. End-of-treatment blood pressures were calculated as the average of values obtained at weeks 11 and 12. Baseline values were included as covariates in blood pressure models. Models for blood pressures and other outcome variables initially contained terms for treatment group, research site and treatment group by site interaction. If terms were not significant at the 0.05 level, the model was reduced in a stepwise manner until only significant terms or treatment group remained. In cases where significant treatment by site interactions were present, the data were examined to assess the degree of heterogeneity between sites and the appropriateness of presenting pooled results for the two sites. Possible differences in the frequency of adverse events (overall and by body system) were assessed with w 2 tests.
Selected subgroup analyses were carried out for treatment responses as defined before database lock in the statistical analysis plan for the trial. These included analyses according to gender, use of antihypertensive medication (yes vs no) and body mass index (BMI) (split at the median). No material differences in response were observed across gender and medication use subgroups. Accordingly, only data for the BMI subgroup analyses are presented.
Results
Subject disposition
A total of 497 subjects were screened. Of these, 49 were randomized to the b-glucan treatment group and 48 to the control group. Among the 400 subjects who did not qualify for the study, 56.2% had a blood pressure that fell either below the minimum for inclusion (27.2%) or above the maximum (29%). The number of randomized subjects who completed the study did not differ significantly between groups, although there was a trend (P ¼ 0.091) toward greater discontinuation in the b-glucan group (n ¼ 22) compared to the control group (n ¼ 13). Table 2 summarizes the baseline characteristics of the perprotocol sample according to treatment group. The mean age of subjects in the b-glucan group was 63 vs 57 years in the controls (P ¼ 0.017). Mean body weights in the b-glucan and control groups were 92.9 and 93.1 kg and mean BMIs were 32.6 and 32.2 kg/m 2 , respectively. More than half of the subjects were clinically obese, as indicated by a median BMI of 31.5 kg/m 2 .
Baseline characteristics
Physical activity and anthropometrics
Although there was a significant difference between groups in physical activity at baseline (metabolic equivalent-hours of 270 for the b-glucan group vs 295 for the control group, P ¼ 0.03), there were no significant differences between the groups in physical activity at week 12 or in the change from baseline (week 0) to week 12.
There were neither statistically significant nor clinically important changes in anthropometric variables within or between the treatment groups (data not shown). Subjects in both the b-glucan and control groups gained a mean of less than 1 kg from week À4 to 12 (data not shown).
Compliance with study food consumption Adequate compliance (defined as consumption of X80% of the scheduled intakes of study product) differed significantly in the intent-to-treat sample, with higher rates of compliance in the control group than the b-glucan group (85-87 vs 64-68%, Po0.05). Compliance among subjects in the per-protocol population was 490% and did not differ significantly between groups.
Dietary intakes
No differences between groups were noted for dietary intakes based on 3-day diet records collected at weeks À2 and 0. At weeks 4 and 12, mean dietary intakes in both treatment groups were consistent with the TLC diet, except for saturated fatty acids. Although the TLC diet guidelines recommend that saturated fatty acid constitute less than 7% of total energy intake, saturated fatty acids represented 7 and 8% of total energy intake at weeks 4 and 12, respectively, for the control group and 8% at both weeks 4 and 12 for the b-glucan group.
There were no significant differences between groups in the changes from weeks 0 to 12 in carbohydrate, protein or total fat intakes ( Table 3) . As expected, total, soluble and insoluble fiber intakes increased significantly more in the b-glucan group than among controls (all Po0.01). Differences in some mineral intakes that have the potential to influence blood pressure were observed. Magnesium intake was 118 mg/day higher in the b-glucan group than in the control group (Po0.001). This difference can be accounted for by the magnesium content of the study products and is due to the naturally high magnesium content of oats. The b-glucan-containing products contained 120 mg/day more magnesium than the control products. In contrast, calcium consumption tended to increase more in the control group (391 mg/day) than in the b-glucan group (135 mg/day, P ¼ 0.052 vs controls).
Blood pressure
Neither systolic nor diastolic blood pressures or blood pressure responses to treatment showed statistically significant differences between treatment groups at any time point in the overall study sample (data not shown).
Prespecified analyses were conducted by BMI subgroup using the median value as a cutpoint. Among subjects in the high-BMI group (431.5 kg/m 2 ), both systolic and diastolic blood pressures showed significant differences between the b-glucan and control treatments in the changes from baseline to week 4 and end of treatment (Figure 1a) . Subjects in the high-BMI b-glucan group exhibited mean baseline to end-of-treatment changes in systolic and diastolic blood pressures of À5.6 and À2.1 mm Hg, respectively, whereas high-BMI control subjects exhibited increases of 2.7 and 1.9 mm Hg (P ¼ 0.008 and 0.018, respectively vs the b-glucan group). No significant differences in blood pressure responses were observed in the low-BMI subset (Figure 1b ).
Glucose and insulin concentrations
Fasting glucose concentrations did not differ significantly between groups at any time point during the study (Table 4) . Fasting insulin concentrations were higher (Po0.01) in the control subjects at weeks 0 and 12, but the changes from week 0 to 12 did not differ significantly between the control and b-glucan groups (Table 4) . Mean peak and incremental AUC values for glucose and insulin after consumption of a standard breakfast containing the control ready-to-eat cereal did not differ between groups at week À2 (Table 4) . Mean peak and incremental AUC values for glucose and insulin tended to be lower at week 0 in the b-glucan group, although differences did not reach statistical significance (Table 4) . Mean values for the glucose (P ¼ 0.042) and insulin (P ¼ 0.044) incremental AUC were significantly lower at week 12 in the b-glucan group compared to controls. Changes in glucose responses from week 0 to 12 did not differ significantly between groups. However, changes in both mean peak (P ¼ 0.037) and incremental AUC (P ¼ 0.034) values for insulin from weeks 0 to 12 were reduced significantly in the b-glucan group compared with changes in the control group. Effects of b-glucan on BP and carbohydrate metabolism KC Maki et al Mean fasting insulin level was significantly higher in the high-BMI subgroup compared to the low-BMI subgroup at week À2 (103.5713.9 vs 59.075.6 pmol/l, Po0.001) and at subsequent time points. However, the general patterns observed in the BMI subgroups for changes from week À2 to 0 and week 0 to 12 in fasting and postprandial glucose and insulin variables were similar to those in the overall study sample (data not shown).
Biomarkers of oxidative stress
No differences were observed between groups in the four measured biomarkers of oxidative stress (results for these variables are shown in Supplementary appendix and table).
Tolerability
No differences between groups were observed in the overall frequency of adverse events. Gastrointestinal side effects that might be expected from fermentation of b-glucan in the large intestine such as cramping and bloating were not reported significantly more often in the b-glucan group compared to controls (data not shown). However, the incidence of diarrhea/loose stools was significantly higher in the b-glucan group compared to controls (P ¼ 0.03).
Discussion
The results of the present trial provide some support for the view that consumption of foods containing b-glucan from oats had favorable effects on postprandial insulin levels in the entire study sample and on blood pressure in obese subjects. Peak postprandial insulin and the incremental area under the postprandial insulin curve were both reduced after 12 weeks of b-glucan consumption. In addition, among subjects with BMI above the median value, both systolic (8.3 mm Hg) and diastolic (3.9 mm Hg) blood pressures were significantly lowered relative to the response in the control group.
When consumed together with a meal or glucose load, dietary fibers that form viscous gels in the gastrointestinal tract have been shown to reduce glycemic responses (Wolever et al., 1991a, b) , and this effect is amplified with repeated dosing for several weeks (Groop et al., 1993; Ebeling et al., 1998) . The blunted glycemic response is generally attributed to mechanical slowing of glucose absorption, although effects on gut hormones (e.g., gastric inhibitory peptide) and insulin secretion and/or clearance may also contribute, particularly to amplification of the effect with repeated dosing (Groop et al., 1993; Ebeling et al., 1998) . Even in the absence of increased peripheral insulin sensitivity, blunted postprandial insulin levels may improve blood pressure by lowering day-long insulin concentrations, and thus reducing the influence of insulin on renal sodium reabsorption, sympathetic activity and anabolic processes (Landsberg, 1999; Fonseca, 2003; Scott, 2003) .
Increasing BMI is generally characterized by greater insulin resistance and compensatory hyperinsulinemia (Reaven et al., 1996; Fonseca, 2003; Haffner and Taegtmeyer, 2003; Scott, 2003) . At week À2, subjects in the high-BMI category had a mean fasting insulin concentration that was 75% higher than that of subjects in the lower BMI category (103.5 vs 59.0 pmol/l). Reduced insulinemia, whether owing to alterations in the dynamics of glucose absorption and insulin secretion, or enhanced insulin sensitivity, might be expected to have the largest effect on blood pressure in those with the greatest hyperinsulinemia at baseline. This may explain the divergent effects on blood pressure observed in the low-and high-BMI subgroups in the present trial, as well as the inconsistent findings from previous studies of the effects of viscous fiber intake on blood pressure (Landin et al., 1992; He et al., 1995 , Burke et al., 2001 Saltzman et al., 2001; Keenan et al., 2002; Pins et al., 2002; Davy et al., 2002; Bazzano et al., 2003) . However, as the differential influence according to baseline BMI is based on a subgroup analysis, At week 2, subjects consumed a standardized breakfast consisting of 4 oz skim milk with one study serving of cold control cereal. At weeks 0 and 12, subjects in the b-glucan and control groups consumed either a cereal containing oat b-glucan or the control cereal, respectively. b P-values for between-treatment comparisons.
this possibility should be viewed as a hypothesis that requires confirmation in future trials designed to address this question directly. a-Glucosidase inhibitors, such as acarbose and miglitol, slow the absorption of glucose by delaying digestion of starches in the small intestine (Chiasson and Naditch, 2001) . Like viscous soluble fibers, these compounds reduce postprandial blood glucose and insulin excursions. Several investigations have reported increased whole-body insulin sensitivity after treatment with an a-glucosidase inhibitor in obese subjects with glucose intolerance (Calle-Pascual et al., 1996; Chiasson et al., 1996; Meneilly et al., 2000) , although others have failed to find such an effect (Schnack et al., 1989; Reaven et al., 1990; Jenney et al., 1993) .
In STOP-NIDDM, acarbose treatment of subjects with impaired glucose tolerance and a mean BMI of B31 kg/m 2 produced modest, but statistically significant, reductions in systolic and diastolic blood pressures (1-2 mm Hg) compared to placebo (Chiasson et al., 2003) . Acarbose treatment was also associated with significant reductions in new-onset hypertension (34%), cardiovascular events (49%) and diabetes mellitus (25%) during 3.3 years of follow-up (Chiasson et al., 2002 (Chiasson et al., , 2003 , illustrating the potential clinical importance of interventions intended to reduce postprandial glucose and insulin levels by slowing carbohydrate absorption (Maki, 2004a, b) . The relative importance of blunting postprandial glucose and insulin responses vs possible changes in peripheral insulin sensitivity to the blood pressure effects of a-glucosidase inhibitors and soluble fibers is unclear at present. Keenan et al. (2002) found blood pressure reductions of 7.5 mm Hg (systolic) and 5.5 mm Hg (diastolic) in hyperinsulinemic men and women with hypertension who consumed oat cereal containing 5.5 g/day of b-glucan. A trend (P ¼ 0.09) toward a lower insulin response to an oral glucose load was observed in the oat cereal group, whereas there was no change in the control group that consumed a low-fiber wheat cereal. Insulin sensitivity, measured with minimal model evaluation of glucose and insulin responses to an intravenous glucose load, was unchanged in either group . These results suggest that the ability of viscous soluble fibers to lower blood pressure may not be dependent on enhancement of peripheral insulin sensitivity.
In contrast, Landin et al. (1992) found that consuming 10 g granulated guar three times daily with meals for 6 weeks produced mean reductions in systolic and diastolic blood pressures of 5 and 3 mm Hg, respectively. These changes were associated with significant increases in sodium and potassium excretion, enhanced insulin sensitivity (whole-body insulin-mediated glucose disposal) and increased insulinstimulated glucose uptake by abdominal fat cells.
Dietary changes other than soluble fiber intake could have played a role in the blood pressure reduction observed in the high-BMI b-glucan subgroup. Diet record analyses indicated trends toward lower sodium and calcium, and higher potassium intakes during the treatment period among subjects assigned to the b-glucan group. In addition, magnesium consumption was significantly higher among subjects assigned to the b-glucan group.
In the Trials of Hypertension Prevention, magnesium supplements (360 mg/day) were shown to have no effect on blood pressure after 3 or 6 months in men and women with baseline diastolic blood pressures of 80-89 mm Hg (Yamamoto et al., 1995; Whelton et al., 1997) . Sodium restriction that resulted in a reduction of B40% in urinary sodium excretion produced mean reductions of 2.1 and 1.2 mm Hg, respectively, in systolic and diastolic blood pressures (Whelton et al., 1997) . Based on diet record analyses, the difference in sodium intake between treatment groups in the present study was B20%. In addition, mean daily potassium intake at week 12 was B11% (273 mg/day) higher in the b-glucan group than in the control group (P ¼ 0.209). Supplementing a low-potassium diet (1250-1380 mg/day) with B3100 mg/day potassium has been shown to significantly reduce systolic and diastolic blood pressures (Brancati et al., 1996) . Each incremental increase in potassium excretion of B390 mg/day was associated with a 0.8 mm Hg decrease in systolic blood pressure and a 0.3 mm Hg decrease in diastolic blood pressure. Therefore, the blood pressure reductions observed in the present trial are unlikely to be attributable solely to changes in mineral intakes. Nevertheless, in studies evaluating the effects of whole foods, it is usually not possible to isolate the contributions of individual components. Whole-grain products are leading sources of several dietary factors that are associated with blood pressure reduction, such as fiber, magnesium and potassium (Lin et al., 2003) . Thus, when consumed as whole foods, the effects of multiple dietary changes may contribute in an additive or synergistic manner.
The present study had a number of limitations that justify caution. These include restriction of the blood pressure effects to the high-BMI subgroup, a relatively high rate of subject attrition and trends toward differential rates of compliance and dropout between the groups. The latter observations could be explained by lower tolerability and/or palatability of the oat-b-glucan-containing study foods. Loose stool was the only gastrointestinal adverse experience reported more frequently among subjects in the b-glucan group compared to controls. Therefore, in the authors' view, the tendencies for subjects in the b-glucan group to show lower compliance and greater dropout appear more likely to be related to palatability than toleration of the study products.
A discussion of the findings regarding biomarkers of oxidative stress may be found in Supplementary appendix and table.
The results of this trial provide some evidence to support a favorable effect of consuming foods containing b-glucan from oats on blood pressures in obese subjects. The reductions in peak and incremental postprandial insulin areas observed in the oat b-glucan group support the hypothesis that alterations in carbohydrate homeostasis may have played a role in the favorable blood pressure changes observed in the high-BMI subgroup. Additional research is needed to test this hypothesis and define the mechanisms by which repeated consumption of viscous soluble fiber enhances the blunting of postprandial insulin responses.
